Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways.
A-498
CAKI-2
Ras/MAPK and PI3K/AKT pathways
apoptosis
human renal cancer
shikonin
targeted therapy
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
22
08
2023
revised:
15
09
2023
accepted:
19
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
(1) Background: Shikonin, the main ingredient in Chinese herbal medicine, is described as a novel angiogenesis inhibitor, and its anticancer effects have already been studied. Shikonin and its derivatives induce apoptosis and suppress metastasis, which further enhance the effectiveness of chemotherapy. However, their mechanism of function has not been completely elucidated on human renal cancer cells. (2) Methods: In our study, CAKI-2 and A-498 cells were treated with increasing concentrations (2.5-40 µM) of shikonin, when colony formation ability and cytotoxic activity were tested. The changes in the expression of the main targets of apoptotic pathways were measured by RT-qPCR and Western blot. The intracellular levels of miR-21 and miR-155 were quantified by RT-qPCR. (3) Results: Shikonin exerted a dose-dependent effect on the proliferation of the cell lines examined. In 5 µM concentration of shikonin in vitro elevated caspase-3 and -7 levels, the proteins of the Ras/MAPK and PI3K/AKT pathways were activated. However, no significant changes were detected in the miR-21 and miR-155 expressions. (4) Conclusions: Our findings indicated that shikonin causes apoptosis of renal cancer cells by activating the Ras/MAPK and PI3K/AKT pathways. These effects of shikonin on renal cancer cells may bear important potential therapeutic implications for the treatment of renal cancer.
Identifiants
pubmed: 37764501
pii: molecules28186725
doi: 10.3390/molecules28186725
pmc: PMC10534756
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union and the European Regional Development Fund
ID : GINOP-2.3.4-15-2016-00002
Organisme : Thematic Excellence Program
ID : TKP2021-EGA-19
Références
Molecules. 2016 Jun 16;21(6):
pubmed: 27322220
Cancer Metastasis Rev. 2018 Mar;37(1):33-44
pubmed: 29282605
Curr Mol Med. 2018;18(5):322-334
pubmed: 30360736
Cancers (Basel). 2021 Aug 28;13(17):
pubmed: 34503172
Ther Clin Risk Manag. 2007 Jun;3(2):341-8
pubmed: 18360643
Mol Ther Nucleic Acids. 2020 Jun 5;20:409-420
pubmed: 32244168
Front Pharmacol. 2022 Jul 01;13:905755
pubmed: 35847041
Eur J Pharmacol. 2022 Oct 15;932:175233
pubmed: 36038011
Biosci Rep. 2018 Apr 13;38(2):
pubmed: 29449346
Mol Med Rep. 2019 May;19(5):4335-4343
pubmed: 30942433
Sci Rep. 2018 Feb 20;8(1):3317
pubmed: 29463831
Cancers (Basel). 2022 Feb 22;14(5):
pubmed: 35267423
PLoS One. 2018 Jun 11;13(6):e0197890
pubmed: 29889836
Onco Targets Ther. 2019 Apr 09;12:2605-2614
pubmed: 31118661
Amino Acids. 2011 Jul;41(2):271-90
pubmed: 20640864
BMC Cancer. 2013 Dec 06;13:580
pubmed: 24314238
Biochem Cell Biol. 2019 Aug;97(4):397-405
pubmed: 30475643
Mol Pathol. 1998 Apr;51(2):55-61
pubmed: 9713587
Cancer Res. 2011 Oct 1;71(19):6208-19
pubmed: 21852381
Ther Clin Risk Manag. 2006 Mar;2(1):87-98
pubmed: 18360584
BMC Cancer. 2019 Jan 7;19(1):20
pubmed: 30616572
Int J Mol Sci. 2015 Oct 09;16(10):23823-48
pubmed: 26473829
Oncol Rep. 2015 Apr;33(4):1571-8
pubmed: 25682771
J Transl Med. 2017 May 31;15(1):123
pubmed: 28569199
Virchows Arch. 2005 May;446(5):475-82
pubmed: 15856292
Chin Med. 2019 Mar 12;14:7
pubmed: 30911326
Cancer Lett. 2019 Sep 10;459:248-267
pubmed: 31132429
Eur Urol. 2019 Jan;75(1):74-84
pubmed: 30243799
Mol Med Rep. 2017 Sep;16(3):3055-3060
pubmed: 28713949
Mol Med Rep. 2017 Aug;16(2):1347-1352
pubmed: 28627658
PLoS One. 2014 Apr 08;9(4):e94180
pubmed: 24714453
Exp Ther Med. 2017 May;13(5):2286-2292
pubmed: 28565840
Toxicol Res (Camb). 2018 Jun 6;7(5):907-912
pubmed: 30310667
Urology. 2011 Aug;78(2):474.e13-9
pubmed: 21820586
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):464-472
pubmed: 29440068
Oncol Lett. 2017 Oct;14(4):4270-4276
pubmed: 28943938
G Ital Nefrol. 2022 Jun 20;39(3):
pubmed: 35819037
Mol Cancer Ther. 2002 Apr;1(6):427-34
pubmed: 12477055
J Biomed Sci. 2015 Apr 01;22:26
pubmed: 25879420
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):626-635
pubmed: 30873870
Cell Physiol Biochem. 2018;47(3):981-993
pubmed: 29843123
Biochem Pharmacol. 2019 Aug;166:33-45
pubmed: 31071331
PLoS One. 2013;8(1):e55168
pubmed: 23383094
Mol Med Rep. 2018 Oct;18(4):3882-3890
pubmed: 30106133
Cancers (Basel). 2021 Feb 20;13(4):
pubmed: 33672520
Thromb Haemost. 2017 Feb 28;117(3):529-542
pubmed: 27975100
Curr Med Chem. 2006;13(16):1845-57
pubmed: 16842197
Mol Med Rep. 2012 Apr;5(4):949-54
pubmed: 22307849
Oncotarget. 2015 Nov 17;6(36):38934-51
pubmed: 26472107
AAPS J. 2017 Nov 30;20(1):8
pubmed: 29192381
Exp Ther Med. 2018 Feb;15(2):1484-1492
pubmed: 29434733
Oncogene. 2006 Oct 9;25(46):6176-87
pubmed: 17028597
Biochem Biophys Res Commun. 2018 Oct 20;505(1):1-6
pubmed: 30224056
Int J Gynecol Pathol. 2014 Jan;33(1):45-51
pubmed: 24300535